I-Mab Biopharma (IMAB) Company Total Revenue

I-Mab is reorganizing its operations by shifting priorities toward US developments, which is temporarily increasing R&D costs. Efficiency is improving through the implementation of AI and robotics for antibody analysis. Complex patent laws and regulations in the US and China create significant barriers. The company's sales volume demonstrates the market resilience of the model, while the level of 0.00 represents the current value of this metric.

IMAB - I-Mab Biopharma Co., Ltd. Company Revenue over the range 07/04/2022 - 10/30/2025

Analytical breakdowns for I-Mab Biopharma Co., Ltd. (IMAB)

- stock value and consensus price forecast:

Stock Quotes I-Mab Inc.|IMAB - Price Target Chart

- market capitalization details:

Market Value I-Mab Biopharma|IMAB - Total Company Value

- book value of equity indicators:

Net Assets per Single Share I-Mab|IMAB - Company Book Value|Market-to-Book Ratio i-mabbiopharma.com|IMAB - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

IMAB - Net Profit|Expected Net Profit I-Mab|IMAB - Price to Earnings Ratio|Future Price to Earnings Multiple I-Mab Inc.|IMAB - PEG Multiple|EV/EBITDA Multiple I-Mab Biopharma|IMAB - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months I-Mab|IMAB - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months i-mabbiopharma.com|IMAB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year I-Mab

- sales volume and revenue indicators:

IMAB - Company Sales|Company Sales Forecast I-Mab Inc.|IMAB - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple I-Mab Biopharma

General company analysis:i-mabbiopharma.com - IMAB

Mass-produced product of I-Mab Biopharma

Revenue directly reflects the commercialization efficiency of I-Mab (IMAB) developments within the immuno-oncology sector. This metric measures the cash flow from product sales, where the company's consolidated sales trend serves as an indicator of market adoption for its antibodies. Steady growth confirms the success of global partnerships and the R&D strategy. It is critical for investors to correlate this data with clinical trial phases. The final trend determines the business's resilience to drawdowns.

Competing companies